Daxor has patented a method for analyzing blood and providing personalized treatment recommendations based on the analysis. The system calculates blood volume, plasma volume, and red cell volume, offering guidance on administering fluids, blood products, or adjusting medication doses to correct blood volume imbalances in patients. GlobalData’s report on Daxor gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Daxor Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Daxor, Sleep quality monitoring was a key innovation area identified from patents. Daxor's grant share as of February 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.

Blood volume correction treatment system and method

Source: United States Patent and Trademark Office (USPTO). Credit: Daxor Corp

A recently granted patent (Publication Number: US11862311B2) outlines a method for treating patients to correct blood volume based on individualized analysis. The method involves using a system that automatically analyzes blood samples to calculate blood volume, plasma volume, and red cell volume for the patient. By inputting patient data and ideal volume calculations, the system provides personalized treatment recommendations such as administering fluids, blood products, or adjusting diuretic drug doses. The treatment can include various interventions like dialysis, ultrafiltration, or therapeutic phlebotomy based on the patient's specific blood volume needs. The system also allows for customization of treatment protocols and interactive presentation of recommendations to healthcare providers.

Furthermore, the patent describes a system that not only analyzes blood volume but also administers quantified patient-individualized treatments through a volume correction subsystem. This system includes components like controllable IV valves for fluids and blood products, as well as devices for ultrafiltration and erythrocytapheresis. Additionally, continuous monitoring of hematocrit levels allows for real-time updates to treatment recommendations. The system ensures human operator approval before treatment administration, with the option for pre-approval based on measurement results. Customizable protocols can incorporate additional patient information beyond volume measurements, catering to specific conditions like heart failure, renal failure, or sepsis. Overall, the patented system offers a comprehensive approach to correcting blood volume in patients with various medical conditions, enhancing personalized care and treatment outcomes.

To know more about GlobalData’s detailed insights on Daxor, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.